MP42-05 THE EXPRESSION LEVEL OF PD-L1 IS CORRELATED WITH CLINICOPATHOLOGICAL CHARACTERISTICS OF PATIENTS WITH VHL-RELATED RENAL CELL CARCINOMA

Abstract

You have accessJournal of UrologyKidney Cancer: Localized: Surgical Therapy III (MP42)1 Sep 2021MP42-05 THE EXPRESSION LEVEL OF PD-L1 IS CORRELATED WITH CLINICOPATHOLOGICAL CHARACTERISTICS OF PATIENTS WITH VHL-RELATED RENAL CELL CARCINOMA Kaifang Ma, Kenan Zhang, Lin Cai, and Kan Gong Kaifang MaKaifang Ma More articles by this author , Kenan ZhangKenan Zhang More articles by this author , Lin CaiLin Cai More articles by this author , and Kan GongKan Gong More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002063.05AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Von Hippel-Lindau (VHL) disease is an autosomal-dominant hereditary cancer syndrome, which characterized by renal cell carcinoma and central nervous system hemangioblastoma. Currently, the expression level and clinical significance of PD-1/PD-L1 in VHL-associated renal cell carcinoma (RCC) remain unclear. This study aimed to explore the correlation of PD-L1 expression with clinicopathological features in patients with VHL-related RCC. METHODS: Patients diagnosed with VHL disease and received nephrectomy were recruited. The clinicopathological features and prognosis of the patients were evaluated. The expression of RCC-associated molecular markers was detected by immunohistochemistry. RESULTS: From Dec. 2009 to Dec. 2020, 57 patients with VHL disease were eligible and included in this study. The median age of these patients were 43 years (IQR 31.5-51), the median follow-up period were 36 months (IQR 13-68.5) and the mean size of the renal tumors were 4.19±1.96 cm (range 1.3-10.5). The study about 112 renal tumors showed that 98.2% pathological type was clear-cell RCC, 89.3% pathological stage was pT1 and 69.6% Fuhrman nuclear grade was G1 in VHL-related RCC. The positive PD-L1, TFE-3, CA-9 and CD10 expression were 24.6%, 28%, 70.6% and 43.2%, respectively. The study revealed that positive PD-L1 expression was associated with higher pathological T stage (p <0.037) and advanced Fuhrman nuclear grade (p <0.007). CONCLUSIONS: PD-L1 expression was associated with aggressive clinicopathological features in patients with VHL-related RCC. Larger prospective studies are warranted to further evaluate whether PD-L1 expression level in CCRCC is related to the effectiveness of PD-1/PD-L1 checkpoint inhibitor immunotherapy. Source of Funding: This study was funded by the National Natural Science Foundation of China (No. 81572506 and 81872081) © 2021 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e772-e773 Advertisement Copyright & Permissions© 2021 by American Urological Association Education and Research, Inc.MetricsAuthor Information Kaifang Ma More articles by this author Kenan Zhang More articles by this author Lin Cai More articles by this author Kan Gong More articles by this author Expand All Advertisement Loading ...